Linde plc · LIN · FY2026 Q1 · Calendar Q2 2026
Linde Q1 2026: EPS $4.33 Beats on Americas Strength, Helium Tightness and Space Push
Linde's Q1 2026 results reinforce a dual narrative: a resilient industrial-gas core anchored by Americas strength and electronics demand, layered with emerging high-growth optionality in commercial space and helium pricing. The 30% operating margin held steady year-over-year despite European softness, and management raised the low end of FY EPS guidance, signaling confidence in backlog conversion and disciplined capital allocation. The key question for investors is whether the helium shortage tailwind and commercial-space ramp can offset persistent European weakness and U.S. health-care policy headwinds over the remainder of FY2026.
Company context
Snapshot as of publicationLinde plc functions as a global industrial gas and engineering powerhouse, extending its operations throughout North and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company's comprehensive product line features atmospheric gases like oxygen, nitrogen, argon, and various rare gases, alongside a diverse array of process gases such as carbon dioxide, helium, hydrogen, specialized electronic gases, and acetylene. Beyond gas supply, Linde is also adept at designing and constructing turnkey process plants. These engineering solutions serve both third-party customers and its own gas business facilities, covering types like olefin, natural gas, air separation, hydrogen, and synthesis gas plants. Linde's extensive client base spans numerous sectors, including healthcare, energy, general manufacturing, food and beverage carbonation, fiber-optics, steel production, aerospace, chemicals, and water treatment. Established in 1879, the company is headquartered in Woking, United Kingdom.
Earnings scorecard
Reported versus consensusEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 11, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BMO Capital | Outperform | Outperform | Maintain | Aug 10, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 3, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 3, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Aug 3, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 10, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 4, 2026 |
| Seaport Global | Buy | Buy | Maintain | Apr 17, 2026 |
| UBS | Buy | Buy | Maintain | Apr 9, 2026 |
| B of A Securities | Buy | Buy | Maintain | Nov 3, 2025 |
| Mizuho | Outperform | Outperform | Maintain | Feb 7, 2025 |
| TD Cowen | Buy | Hold | Upgrade | Jan 13, 2025 |
| Erste Group | Hold | Buy | Downgrade | Nov 19, 2024 |
| Deutsche Bank | Buy | Buy | Maintain | Nov 1, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 8, 2023 |
| Goldman Sachs | Buy | Buy | Maintain | Dec 15, 2022 |
| HSBC | Buy | Buy | Maintain | Nov 15, 2022 |
| Societe Generale | Buy | Buy | Maintain | Oct 17, 2022 |
| Stifel | Buy | Hold | Upgrade | Aug 10, 2022 |
| Jefferies | Buy | Buy | Maintain | Jun 16, 2022 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jan 11, 2022 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Dec 9, 2021 |
| Vertical Research | Buy | Hold | Upgrade | May 18, 2021 |
| Barclays | Overweight | Equal Weight | Upgrade | Dec 7, 2020 |
| CFRA | Buy | Buy | Maintain | May 7, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Feb 18, 2020 |
| KeyBanc | Overweight | Overweight | Maintain | Jul 9, 2019 |
| Evercore Partners | Equal Weight | Overweight | Downgrade | Aug 25, 2014 |
| Gabelli & Co. | Hold | Buy | Downgrade | Mar 24, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $464.64. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| KeyBanc | Analyst unavailable | $542 | $461.62 | +16.7% | Sep 10, 2026 |
| Goldman Sachs | Analyst unavailable | $580 | $487.37 | +24.8% | Aug 10, 2026 |
| BMO Capital | Analyst unavailable | $546 | $488.14 | +17.5% | Aug 10, 2026 |
| Bernstein | James Hooper | $564 | $482.46 | +21.4% | Aug 3, 2026 |
| RBC Capital | Arun Viswanathan | $553 | $482.25 | +19.0% | Aug 3, 2026 |
| UBS | Analyst unavailable | $612 | $478.38 | +31.7% | Aug 3, 2026 |
| Bernstein | Analyst unavailable | $559 | $520.74 | +20.3% | Jul 17, 2026 |
| Evercore ISI | Analyst unavailable | $525 | $531.79 | +13.0% | Jul 10, 2026 |
| UBS | Joshua Spector | $600 | $494.4 | +29.1% | Jun 2, 2026 |
| BMO Capital | Analyst unavailable | $560 | $495.09 | +20.5% | May 5, 2026 |
| RBC Capital | Analyst unavailable | $570 | $493.55 | +22.7% | May 5, 2026 |
| Deutsche Bank | David Begleiter | $575 | $499.45 | +23.8% | May 4, 2026 |
| RBC Capital | Arun Viswanathan | $552 | $505.73 | +18.8% | Apr 24, 2026 |
| Seaport Global | Analyst unavailable | $575 | $492.8 | +23.8% | Apr 17, 2026 |
| UBS | Joshua Spector | $579 | $503.3 | +24.6% | Apr 9, 2026 |
| Morgan Stanley | Analyst unavailable | $530 | $451.85 | +14.1% | Feb 6, 2026 |
| UBS | Analyst unavailable | $550 | $452.28 | +18.4% | Feb 6, 2026 |
| Mizuho Securities | John Roberts | $525 | $459.69 | +13.0% | Feb 6, 2026 |
| BMO Capital | John McNulty | $501 | $423.51 | +7.8% | Dec 17, 2025 |
| RBC Capital | Arun Viswanathan | $490 | $412.97 | +5.5% | Dec 12, 2025 |
| Mizuho Securities | Analyst unavailable | $495 | $403.32 | +6.5% | Dec 11, 2025 |
| UBS | Joshua Spector | $500 | $420.67 | +7.6% | Nov 11, 2025 |
| Bernstein | James Hooper | $516 | $418.3 | +11.1% | Nov 3, 2025 |
| Seaport Global | Michael Harrison | $500 | $418.3 | +7.6% | Nov 3, 2025 |
| UBS | Analyst unavailable | $507 | $467.61 | +9.1% | Oct 6, 2025 |
| RBC Capital | Arun Viswanathan | $576 | $465.98 | +24.0% | Jun 13, 2025 |
| Evercore ISI | Eric Boyes | $490 | $430.2 | +5.5% | Dec 17, 2024 |
| BMO Capital | John McNulty | $507 | $457.31 | +9.1% | Nov 1, 2024 |
| BMO Capital | John McNulty | $477 | $449.94 | +2.7% | Aug 6, 2024 |
| Bank of America Securities | Steve Byrne | $516 | $454 | +11.1% | Aug 5, 2024 |
| Barclays | Michael Leithead | $510 | $454 | +9.8% | Aug 5, 2024 |
| Citigroup | Pat Cunningham | $480 | $443.5 | +3.3% | Aug 5, 2024 |
| Deutsche Bank | David Begleiter | $510 | $443.5 | +9.8% | Aug 5, 2024 |
| Jefferies | Laurence Alexander | $523 | $440.02 | +12.6% | Jun 20, 2024 |
| BMO Capital | John McNulty | $475 | $425.8 | +2.2% | May 6, 2024 |
| Mizuho Securities | John Roberts | $512 | $419.62 | +10.2% | May 3, 2024 |
| Mizuho Securities | John Roberts | $510 | $446.79 | +9.8% | Apr 18, 2024 |
| UBS | Joshua Spector | $510 | $467.55 | +9.8% | Mar 27, 2024 |
| Wells Fargo | Analyst unavailable | $375 | $339.83 | -19.3% | Feb 8, 2023 |
| Citigroup | Analyst unavailable | $418 | $337.12 | -10.0% | Feb 8, 2023 |
| Goldman Sachs | Analyst unavailable | $375 | $330.07 | -19.3% | Dec 15, 2022 |
| Citigroup | Analyst unavailable | $402 | $342.01 | -13.5% | Dec 15, 2022 |
| HSBC | Analyst unavailable | $375 | $335.04 | -19.3% | Nov 15, 2022 |
| UBS | Analyst unavailable | $320 | $293.37 | -31.1% | Sep 12, 2022 |
| Jefferies | Analyst unavailable | $355 | $290.73 | -23.6% | Jun 16, 2022 |
| Deutsche Bank | Tim Jones | $351.29 | $292.34 | -24.4% | Feb 14, 2022 |
| BMO Capital | John McNulty | $365 | $292.34 | -21.4% | Feb 14, 2022 |
| Mizuho Securities | Chris Parkinson | $339 | $307.62 | -27.0% | Feb 10, 2022 |
| Alembic Global | Hassan Ahmed | $331.71 | $319.88 | -28.6% | Jan 18, 2022 |
| Morgan Stanley | Vincent Andrews | $365 | $335.08 | -21.4% | Jan 11, 2022 |
| Citigroup | PJ Juvekar | $400 | $335.08 | -13.9% | Jan 11, 2022 |
| Wells Fargo | Michael Sison | $395 | $336.66 | -15.0% | Jan 6, 2022 |
| Societe Generale | Peter Clark | $400 | $343.43 | -13.9% | Jan 4, 2022 |
| Wolfe Research | Josh Silverstein | $404 | $330.79 | -13.1% | Dec 9, 2021 |
| Evercore ISI | Stephen Richardson | $355 | $329.33 | -23.6% | Dec 7, 2021 |
| Barclays | Duffy Fischer | $380 | $335.06 | -18.2% | Nov 8, 2021 |
| Norddeutsche Landesbank | Thorsten Strauss | $293.65 | $325.17 | -36.8% | Nov 2, 2021 |
| Vertical Research | Kevin McCarthy | $330 | $293.79 | -29.0% | May 18, 2021 |
Track every rating change on LIN the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session closeFollow LIN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Linde reported Q1 2026 EPS of $4.33 versus a consensus estimate of $4.27 (a 1.4% surprise) and revenue of $8.78 billion versus an estimate of $8.60 billion (a 2.1% surprise). Sales rose 8% year-over-year and EPS grew 10%. The operating margin held at 30%. The market responded modestly on the event session with an abnormal move of +1.08% (benchmark +0.28%), though the stock subsequently drifted -2.07% over the following window on 1.35x baseline volume. Compared to Q4 2025, which posted EPS of $4.20 and a 29.5% operating margin, Q1 showed continued margin and earnings improvement. The most notable shifts quarter-over-quarter: guidance sentiment moved from maintained to raised, the bullish score increased from 70 to 75, capex outlook shifted from increasing to stable at approximately $1.3 billion annually, and management flagged a new acute helium shortage alongside a more ambitious commercial-space timeline targeting $1 billion-plus in revenue potentially earlier than 2030.
Guidance delta
Management raised the lower end of full-year EPS guidance, with the prior quarter's range standing at $17.40 to $17.90. The guidance sentiment moved from maintained in Q4 2025 to raised in Q1 2026. Management expects margin expansion despite assuming no broader economic improvement. Capex outlook shifted from increasing to stable at approximately $1.3 billion annually, split between base spend and project backlog. The company also announced a 7% dividend increase and $800 million in share repurchases.
Key takeaways
- EPS of $4.33 beat consensus by 1.4%; revenue of $8.78B beat by 2.1%, with sales up 8% YoY and EPS up 10%.
- Operating margin held at 30%, up from 29.5% in the prior quarter, despite continued European industrial weakness.
- Americas delivered the strongest volume and pricing growth; Europe remained soft; APAC was seasonal.
- Helium shifted from oversupply to an acute global shortage, providing pricing upside with 85 to 90% of customers under long-term contracts.
- Commercial space services are being positioned as a new high-growth line, targeting $1B-plus in revenue (5% of sales) potentially earlier than 2030.
- Full-year EPS guidance was raised at the low end, with expectations of margin expansion assuming no economic improvement.
Management priorities
- Add substantial new projects to the ultra-high-purity plant backlog within the year.
- Grow the commercial space propellant business toward the 5% of sales target.
- Maintain disciplined capital allocation with $1.3B annual capex split between base spend and project backlog.
- Continue shareholder returns via dividend growth (raised 7%) and $800M share repurchases.
- Pursue additional bolt-on acquisitions, especially in the Americas.
Related earnings events
Basic MaterialsSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-28T12:11:48.792804+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T12:11:48.789961+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.